

## COMPANY OVERVIEW

Aurinia is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerular sclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).

## RECENT NEWS

### Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

Jun 21 2019, 6:30 AM EDT

## STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	567.29m
Last Price	\$6.19
52-Week Range	\$5.06 - \$7.85

06/25/2019 04:00 PM EDT

## INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH  
Corporate Communications  
[IR@auriniapharma.com](mailto:IR@auriniapharma.com)

## MANAGEMENT TEAM

**Peter Greenleaf, MBA**  
Chief Executive Officer, Director

**Neil Solomons, M.D.**  
Chief Medical Officer

**Michael Martin**  
Chief Operating Officer

**Dennis Bourgeault**  
Chief Financial Officer

**Robert Huizinga, Ph.D., R.N., CNeph(C)**  
Executive Vice President, Corporate Development

**Erik Eglite, D.P.M., J.D., M.B.A.**  
Senior Vice President, General Counsel & Chief  
Corporate Compliance Officer

**Rashieda Gluck**  
Senior Vice President, Global Clinical Operations

**Ron Demers**  
Vice President, Manufacturing and Supply Chain

**Lawrence (Larry) D. Mandt**  
Vice President, Quality & Regulatory Affairs

**Bradley J. Dickerson**  
General Manager, Americas & Global Commercial Lead

**Sue Evans, MBA, RAC**  
Head, Regulatory Affairs

**Simrat Randhawa, M.D., M.B.A.**  
Senior Vice President, Clinical & Medical Affairs

## AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street  
Victoria, BC V8Z 7X8  
Canada

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.